Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation

Maurizio Taramasso, Francesco Maisano, Azeem Latib, Paolo Denti, Nicola Buzzatti, Micaela Cioni, Giovanni La Canna, Antonio Colombo, Ottavio Alfieri

Research output: Contribution to journalArticle

Abstract

Aims: The aim of this study was to report medium-term outcomes of MitraClip implantation in inoperable or high-risk surgical candidates with functional mitral regurgitation (FMR) in our single-centre experience.

Methods and results: From October 2008, 109 consecutive patients with FMR underwent MitraClip implantation (mean age 69±9 years; 82- NYHA Class III-IV). Logistic EuroSCORE was 22±16-. Comorbidities included: chronic renal failure (47-), diabetes (22-), COPD (28-). Mean EF was 28±11-; LVEDD was 68±8 mm. Procedural success was 99- and 30-day mortality was 1.8-. At discharge, 87- patients had MR ≤2+. At 12 months, EF was 34.7±10.4- (p=0.002 compared to preoperative value). Actuarial survival at three years was 74.5±7-. Actuarial freedom from MR ≥3+ at 2.5 years was 70±6-. At one-year follow-up, 86- of patients were in NYHA Class I-II. Preoperative pro-BNP level ≥1,600 pg/ml was identified as an independent risk factor of mortality at follow-up.

Conclusions: MitraClip therapy for FMR is a valuable alternative to surgery in high-risk patients. Higher preoperative pro-BNP level is a risk factor for mortality at follow-up. Although patients treated in current practice are high-risk, the procedure remains safe and effective in selected patients.

Original languageEnglish
JournalEuroIntervention
Volume10
Issue number6
Publication statusPublished - Oct 1 2014

Fingerprint

Mitral Valve Insufficiency
Mortality
Chronic Obstructive Pulmonary Disease
Chronic Kidney Failure
Comorbidity
Survival

Keywords

  • Biochemical markers
  • Edge-to-edge repair
  • Mitral valve disease
  • Valvular heart disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Taramasso, M., Maisano, F., Latib, A., Denti, P., Buzzatti, N., Cioni, M., ... Alfieri, O. (2014). Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention, 10(6).

Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. / Taramasso, Maurizio; Maisano, Francesco; Latib, Azeem; Denti, Paolo; Buzzatti, Nicola; Cioni, Micaela; La Canna, Giovanni; Colombo, Antonio; Alfieri, Ottavio.

In: EuroIntervention, Vol. 10, No. 6, 01.10.2014.

Research output: Contribution to journalArticle

Taramasso, M, Maisano, F, Latib, A, Denti, P, Buzzatti, N, Cioni, M, La Canna, G, Colombo, A & Alfieri, O 2014, 'Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation', EuroIntervention, vol. 10, no. 6.
Taramasso M, Maisano F, Latib A, Denti P, Buzzatti N, Cioni M et al. Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention. 2014 Oct 1;10(6).
Taramasso, Maurizio ; Maisano, Francesco ; Latib, Azeem ; Denti, Paolo ; Buzzatti, Nicola ; Cioni, Micaela ; La Canna, Giovanni ; Colombo, Antonio ; Alfieri, Ottavio. / Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. In: EuroIntervention. 2014 ; Vol. 10, No. 6.
@article{4395d3ec2d91461ab98910f3f08e0ee1,
title = "Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation",
abstract = "Aims: The aim of this study was to report medium-term outcomes of MitraClip implantation in inoperable or high-risk surgical candidates with functional mitral regurgitation (FMR) in our single-centre experience.Methods and results: From October 2008, 109 consecutive patients with FMR underwent MitraClip implantation (mean age 69±9 years; 82- NYHA Class III-IV). Logistic EuroSCORE was 22±16-. Comorbidities included: chronic renal failure (47-), diabetes (22-), COPD (28-). Mean EF was 28±11-; LVEDD was 68±8 mm. Procedural success was 99- and 30-day mortality was 1.8-. At discharge, 87- patients had MR ≤2+. At 12 months, EF was 34.7±10.4- (p=0.002 compared to preoperative value). Actuarial survival at three years was 74.5±7-. Actuarial freedom from MR ≥3+ at 2.5 years was 70±6-. At one-year follow-up, 86- of patients were in NYHA Class I-II. Preoperative pro-BNP level ≥1,600 pg/ml was identified as an independent risk factor of mortality at follow-up.Conclusions: MitraClip therapy for FMR is a valuable alternative to surgery in high-risk patients. Higher preoperative pro-BNP level is a risk factor for mortality at follow-up. Although patients treated in current practice are high-risk, the procedure remains safe and effective in selected patients.",
keywords = "Biochemical markers, Edge-to-edge repair, Mitral valve disease, Valvular heart disease",
author = "Maurizio Taramasso and Francesco Maisano and Azeem Latib and Paolo Denti and Nicola Buzzatti and Micaela Cioni and {La Canna}, Giovanni and Antonio Colombo and Ottavio Alfieri",
year = "2014",
month = "10",
day = "1",
language = "English",
volume = "10",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "6",

}

TY - JOUR

T1 - Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation

AU - Taramasso, Maurizio

AU - Maisano, Francesco

AU - Latib, Azeem

AU - Denti, Paolo

AU - Buzzatti, Nicola

AU - Cioni, Micaela

AU - La Canna, Giovanni

AU - Colombo, Antonio

AU - Alfieri, Ottavio

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Aims: The aim of this study was to report medium-term outcomes of MitraClip implantation in inoperable or high-risk surgical candidates with functional mitral regurgitation (FMR) in our single-centre experience.Methods and results: From October 2008, 109 consecutive patients with FMR underwent MitraClip implantation (mean age 69±9 years; 82- NYHA Class III-IV). Logistic EuroSCORE was 22±16-. Comorbidities included: chronic renal failure (47-), diabetes (22-), COPD (28-). Mean EF was 28±11-; LVEDD was 68±8 mm. Procedural success was 99- and 30-day mortality was 1.8-. At discharge, 87- patients had MR ≤2+. At 12 months, EF was 34.7±10.4- (p=0.002 compared to preoperative value). Actuarial survival at three years was 74.5±7-. Actuarial freedom from MR ≥3+ at 2.5 years was 70±6-. At one-year follow-up, 86- of patients were in NYHA Class I-II. Preoperative pro-BNP level ≥1,600 pg/ml was identified as an independent risk factor of mortality at follow-up.Conclusions: MitraClip therapy for FMR is a valuable alternative to surgery in high-risk patients. Higher preoperative pro-BNP level is a risk factor for mortality at follow-up. Although patients treated in current practice are high-risk, the procedure remains safe and effective in selected patients.

AB - Aims: The aim of this study was to report medium-term outcomes of MitraClip implantation in inoperable or high-risk surgical candidates with functional mitral regurgitation (FMR) in our single-centre experience.Methods and results: From October 2008, 109 consecutive patients with FMR underwent MitraClip implantation (mean age 69±9 years; 82- NYHA Class III-IV). Logistic EuroSCORE was 22±16-. Comorbidities included: chronic renal failure (47-), diabetes (22-), COPD (28-). Mean EF was 28±11-; LVEDD was 68±8 mm. Procedural success was 99- and 30-day mortality was 1.8-. At discharge, 87- patients had MR ≤2+. At 12 months, EF was 34.7±10.4- (p=0.002 compared to preoperative value). Actuarial survival at three years was 74.5±7-. Actuarial freedom from MR ≥3+ at 2.5 years was 70±6-. At one-year follow-up, 86- of patients were in NYHA Class I-II. Preoperative pro-BNP level ≥1,600 pg/ml was identified as an independent risk factor of mortality at follow-up.Conclusions: MitraClip therapy for FMR is a valuable alternative to surgery in high-risk patients. Higher preoperative pro-BNP level is a risk factor for mortality at follow-up. Although patients treated in current practice are high-risk, the procedure remains safe and effective in selected patients.

KW - Biochemical markers

KW - Edge-to-edge repair

KW - Mitral valve disease

KW - Valvular heart disease

UR - http://www.scopus.com/inward/record.url?scp=84902781263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902781263&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 6

ER -